Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenocarcinoma of the Prostate: early-phase trial registry
All 22 indexed Adenocarcinoma of the Prostate trials have closed enrollment; the archived set skews early-phase.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · none currently recruiting · #756 of 28,707 conditions by registered trial count
Adenocarcinoma of the Prostate: 22 US clinical trials tracked, none currently recruiting.
Adenocarcinoma of the Prostate is the subject of 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition adenocarcinoma-of-the-prostate
OPEN 0 | RECR 0% | LATE 1 | EARLY 15 | RANK #756 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adenocarcinoma of the Prostate has no open enrollment in this registry pull (22 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenocarcinoma of the Prostate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenocarcinoma of the Prostate is recruiting below its size-band peers.
0 of 22 indexed trials (0%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adenocarcinoma of the Prostate research.
National Cancer Institute (NCI) accounts for 5 of 22 trials (22.7%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Adenocarcinoma of the Prostate trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 22 trials that report a genuine target (sentinel values excluded). 16 of those (72.7%) plan for fewer than 100 participants.
-
Adenocarcinoma of the Prostate research is mostly interventional.
22 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT02296229
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT02176902
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
University of Florida
NCT03624660
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Mark Stein
NCT03689699
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01655836
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
NCT02023463
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03511196
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
NCT00110214
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
National Cancer Institute (NCI)
NCT00438464
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
National Cancer Institute (NCI)
NCT00331344
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02203695
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02523924
Radiation and Androgen Ablation for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01517451
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02225925
Enzalutamide in Patients With High-risk Prostate Cancer
Case Comprehensive Cancer Center
NCT01927627
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
NCT01832259
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
National Cancer Institute (NCI)
NCT00118092
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01533246
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
NCT02184533
Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping
Washington University School of Medicine
NCT00608920
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
University of Southern California
NCT02237612
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
NCT00466752
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenocarcinoma of the Prostate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenocarcinoma of the Prostate trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenocarcinoma of the Prostate page
22 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adenocarcinoma of the Prostate trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Adenocarcinoma of the Prostate trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma of the Prostate condition card totals 22 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.